Readmission After Pancreatic Resection: Causes and Causality Pattern

Annals of Surgical Oncology

Volumn 21, Issue 13, 2014, Pages 4342-4350

  Sadot, Eran ^a   Brennan, Murray F ^a   Lee, Ser Yee ^a   Allen, Peter J ^a   Gönen, Mithat ^a   Groeger, Jeffery S ^a   Peter Kingham, T ^a   D’Angelica, Michael I ^a   DeMatteo, Ronald P ^a   Jarnagin, William R ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ABDOMINAL ABSCESS; ABDOMINAL DRAIN; ABDOMINAL SURGERY; ACINAR CELL CARCINOMA; ACINAR CELL CYSTADENOMA; ADULT; AGE; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CARCINOMA IN SITU; CENTRAL PANCREATECTOMY; CONTROLLED STUDY; CYSTADENOMA; DEEP VEIN THROMBOSIS; DISTAL PANCREATECTOMY; DRAIN MALFUNCTION; EPIDEMIOLOGY; FAILURE TO THRIVE; FEMALE; GASTRIC DYSMOTILITY; GASTROINTESTINAL HEMORRHAGE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MUCINOUS CYSTIC NEOPLASM; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS CYST; PANCREAS DISEASE; PANCREAS FISTULA; PANCREAS ISLET CELL TUMOR; PANCREAS LEAK; PANCREAS METASTASIS; PANCREAS RESECTION; PANCREAS RETENTION CYST; PANCREAS SARCOMA; PANCREATICODUODENECTOMY; PANCREATITIS; PARALYTIC ILEUS; PATIENT HISTORY OF SURGERY; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; PREDICTION; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REOPERATION; SARCOMA; SMALL INTESTINE OBSTRUCTION; SOLID PSEUDOPAPILLARY TUMOR; SURGICAL INFECTION; SURGICAL MORTALITY; UNSPECIFIED SIDE EFFECT; CANCER STAGING; FOLLOW UP; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PATIENT READMISSION; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84911968582     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3841-0     Document Type: Article

References (25)

1. Medicare Payment Advisory Commission. Payment policy for inpatient readmissions. Report to the Congress: promoting greater efficiency in Medicare. http://www.medpac.gov/documents/jun07_entirereport.pdf. Accessed 8 Nov 2013.
2. Centers for Medicare and Medicaid Services. Fact sheet: quality measures for reporting in fiscal year 2009 for 2010 update. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/downloads/HospitalRHQDAPU200808.pdf. Accessed 8 Nov 2013.
3. Readmissions Reduction Program. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html. Accessed 8 Nov 2013.
4. Reddy DM, Townsend CM Jr, Kuo YF, et al. Readmission after pancreatectomy for pancreatic cancer in Medicare patients. J Gastrointest Surg. 2009;13(11):1963–74; discussion 74–5.
5. Yermilov I, Bentrem D, Sekeris E, et al. Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol. 2009;16(3):554–61.
6. Gawlas I, Sethi M, Winner M, et al. Readmission after pancreatic resection is not an appropriate measure of quality. Ann Surg Oncol. 2013;20(6):1781–7.
7. Schneider EB, Hyder O, Wolfgang CL, et al. Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg. 2012;215(5):607–15.
8. Zhu ZY, He JK, Wang YF, et al. Multivariable analysis of factors associated with hospital readmission following pancreaticoduodenectomy for malignant diseases. Chin Med J (Engl). 2011;124(7):1022–5.
9. Fong ZV, Ferrone CR, Thayer SP, et al. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them? A 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg. 2014;18(1):144–5.
10. Tsai TC, Joynt KE, Orav EJ, et al. Variation in surgical-readmission rates and quality of hospital care. N Engl J Med. 2013;369(12):1134–42.
11. Hyder O, Dodson RM, Nathan H, et al. Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surg. 2013;148(12):1095–102.
12. Park J, Pillarisetty VG, Brennan MF, et al. Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg. 2010;211(3):308–15.
13. Correa-Gallego C, Brennan MF, D’Angelica M, et al. Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg. 2013;258(6):1051–8.
14. Vin Y, Sima CS, Getrajdman GI, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg. 2008;207(4):490–8.
15. Kent TS, Sachs TE, Callery MP, Vollmer CM Jr. Readmission after major pancreatic resection: a necessary evil? J Am Coll Surg. 2011;213(4):515–23.
16. Ahmad SA, Edwards MJ, Sutton JM, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg. 2012;256(3):529–37.
17. Emick DM, Riall TS, Cameron JL, et al. Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg. 2006;10(9):1243–52; discussion 52–3.
18. Leichtle SW, Kaoutzanis C, Mouawad NJ, et al. Classic Whipple versus pylorus-preserving pancreaticoduodenectomy in the ACS NSQIP. J Surg Res. 2013;183(1):170–6.
19. ® for pancreatic adenocarcinoma. http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed Nov 2013.
20. Distler M, Pilarsky E, Kersting S, Grutzmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas: a retrospective tumor marker prognostic study. Int J Surg. 2013;11(10):1067–72.
21. Kanda M, Fujii T, Takami H, et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. (Epub 9 Oct 2013).
22. Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139(4):681–9.
23. Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18(6):530–8.
24. Medicare claims processing manual. Chapter 12: physicians/nonphysician practitioners. http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c12.pdf. Accessed 28 April 2014.
25. O’Reilly EM, Lowery MA. Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer J. 2012;18(6):609–13.